Literature DB >> 19062317

Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity.

Anna M Keller1, Anita Schildknecht, Yanling Xiao, Maries van den Broek, Jannie Borst.   

Abstract

Steady-state dendritic cells (DCs) maintain peripheral T cell tolerance, whereas mature DCs generate immunity. CD70 is a costimulatory ligand acquired upon DC maturation. To determine its impact on T cell fate, we have generated mice that constitutively express CD70 in conventional DCs (cDCs). In these mice, naive CD4+ and CD8+ T cells spontaneously convert into effector cells. Administration of peptide without adjuvant, which is ordinarily tolerogenic, elicited tumor-eradicating CD8+ T cell responses and robust CD4+ T cell-independent memory. CD70 was also constitutively expressed in cDCs that inducibly present viral epitopes. In this case, tolerance induction was prevented as well. The antigen-presenting DCs generated protective immunity to virus infection and broke a pre-existing state of CD8+ T cell tolerance. Thus, the sole expression of CD70 by otherwise immature cDCs sufficed to convert CD8+ T cell tolerance into immunity, defining the importance of CD27-CD70 interactions at the interface between T cell and DC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19062317     DOI: 10.1016/j.immuni.2008.10.009

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  67 in total

1.  Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.

Authors:  Shenghe Tian; Zuqiang Liu; Cara Donahue; Louis D Falo; Zhaoyang You
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Reproductive immunology: a focus on the role of female sex hormones and other gender-related factors.

Authors:  Elena Peeva
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

3.  Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.

Authors:  Jianping Huang; Qiong J Wang; Shicheng Yang; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

Review 4.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 5.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

6.  Release of dendritic cells from cognate CD4+ T-cell recognition results in impaired peripheral tolerance and fatal cytotoxic T-cell mediated autoimmunity.

Authors:  Sabine Muth; Kristian Schütze; Hansjörg Schild; Hans Christian Probst
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

7.  Differential requirement of CD27 costimulatory signaling for naïve versus alloantigen-primed effector/memory CD8+ T cells.

Authors:  K Yamaura; O Boenisch; T Watanabe; T Ueno; V Vanguri; J Yang; K Tanaka; I Guleria; J Borst; Y Zhai; J W Kupiec-Weglinski; N Najafian
Journal:  Am J Transplant       Date:  2010-03-26       Impact factor: 8.086

Review 8.  Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.

Authors:  Yuan Zhuang; Sihan Li; Huihui Wang; Jingbo Pi; Yuhui Xing; Guang Li
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

10.  CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production.

Authors:  Victor Peperzak; Yanling Xiao; Elise A M Veraar; Jannie Borst
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.